+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pharmaceutical Contract Development & Manufacturing Market - Global Forecast 2026-2032- Product Image
Pharmaceutical Contract Development & Manufacturing Market - Global Forecast 2026-2032- Product Image
Sale

Pharmaceutical Contract Development & Manufacturing Market - Global Forecast 2026-2032

  • Report

  • 182 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4829832
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Pharmaceutical Contract Development & Manufacturing Market is projected to reach USD 160.20 Billion in 2026. It is expected to continue growing at a CAGR of 8.71%, reaching USD 265.79 Billion by 2032.

Pharmaceutical contract development and manufacturing organizations (CDMOs) have become strategic infrastructure for drug sponsors seeking faster development timelines, resilient supply, specialized manufacturing capacity, and regulatory-grade quality systems. Demand is being shaped by biologics, high-potency active pharmaceutical ingredients, sterile injectables, cell and gene therapies, complex generics, and lifecycle management programs that require advanced formulation, analytical development, process validation, and commercial-scale manufacturing expertise.

The sector is moving beyond transactional outsourcing toward integrated development and manufacturing partnerships. Sponsors are prioritizing CDMOs with proven regulatory inspection histories, scalable capacity, disciplined technology transfer, data integrity controls, and the ability to support quality-by-design, continuous improvement, and global market access. This executive summary evaluates pharmaceutical CDMO market dynamics through regional, group, and country-level lenses while addressing the compounding role of artificial intelligence in pharmaceutical development and manufacturing.

Transformative Shifts in the CDMO Landscape

The pharmaceutical CDMO landscape is being reshaped by supply chain localization, biologics expansion, sterile manufacturing constraints, and heightened regulatory expectations. Public health disruptions, geopolitical risk, and shortages of essential medicines have pushed governments and sponsors to reassess dependence on single-source manufacturing and long-distance active pharmaceutical ingredient supply chains. This is increasing interest in dual sourcing, regional manufacturing networks, and trusted CDMO partners with validated contingency planning.

Scientific complexity is also changing outsourcing criteria. More pipelines now involve large molecules, antibody-drug conjugates, mRNA platforms, peptides, highly potent compounds, and patient-specific therapies. These modalities demand containment infrastructure, aseptic fill-finish capability, advanced analytics, cold-chain readiness, and specialist talent. As a result, competitive advantage is shifting toward CDMOs that can integrate development, clinical manufacturing, regulatory documentation, and commercial production under robust quality management systems.

Cumulative Impact of Artificial Intelligence on CDMOs

Artificial intelligence is creating cumulative gains across pharmaceutical contract development and manufacturing by improving molecule screening, formulation design, process optimization, predictive maintenance, deviation detection, demand forecasting, and regulatory intelligence. In development settings, machine learning supports faster experimental design and more efficient identification of critical process parameters, helping teams reduce failed batches and accelerate technology transfer when combined with validated scientific workflows.

In manufacturing, AI-enabled analytics strengthen real-time monitoring, equipment utilization, and quality risk management. However, adoption is constrained by data quality, model validation, cybersecurity, and regulatory expectations for explainability, validation, and human oversight. CDMOs that align AI deployment with FDA, EMA, ICH Q9(R1), ICH Q10, ICH Q13, and data integrity principles are better positioned to convert automation and advanced analytics into measurable operational reliability rather than isolated digital pilots.

Key Regional Insights Across Global CDMO Markets

Asia-Pacific remains a core growth region for pharmaceutical contract development and manufacturing, led by China, India, Japan, South Korea, Singapore, and Australia. The region benefits from API scale, biologics investment, clinical trial activity, and government support for life sciences manufacturing. China continues to expand biologics and innovative drug manufacturing capacity, while India remains critical for generics, APIs, vaccines, and cost-competitive development services. Japan, South Korea, and Australia add strength in advanced biologics, clinical development, stringent quality expectations, and regulated market access.

North America is defined by high-value innovation, FDA-regulated manufacturing, biologics capacity, sterile injectables, and strong sponsor demand for quality-certified outsourcing. The United States remains the anchor market, while Canada and Mexico support clinical, manufacturing, and nearshoring strategies. Latin America, led by Brazil and Mexico, is gaining relevance through local access needs, public health procurement, and regional supply diversification. Europe is shaped by EMA standards, advanced pharmaceutical clusters, sustainability requirements, serialization, and specialized manufacturing across Germany, France, Italy, Spain, the United Kingdom, Ireland, Belgium, and the Nordics. The Middle East is investing in pharmaceutical self-sufficiency through Saudi Arabia and the United Arab Emirates, with emphasis on local production and medicine security, while Africa’s opportunity is tied to vaccine manufacturing, essential medicines, technology transfer, and public-private capacity building aligned with health security priorities.

Key Group Insights for CDMO Strategy

ASEAN is emerging as a practical manufacturing and clinical supply hub as Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines deepen participation in pharmaceutical value chains. Singapore stands out for biomanufacturing, regulatory maturity, and regional headquarters activity, while other ASEAN members offer cost-efficient production, expanding healthcare demand, and improving industrial infrastructure. For CDMOs, the group supports China-plus-one sourcing, regional packaging, clinical supply logistics, and market access strategies.

The GCC is prioritizing medicine security, local production, and healthcare industrialization, especially in Saudi Arabia and the United Arab Emirates, where national health and industrial strategies are encouraging pharmaceutical localization. The European Union remains one of the world’s most regulated and technologically advanced pharmaceutical manufacturing blocs, with strong demand for GMP compliance, sustainability, serialization, pharmacovigilance readiness, and specialized production. BRICS countries are influential because they combine large populations, expanding healthcare systems, API scale, and domestic manufacturing policy. G7 markets drive premium outsourcing demand through innovation intensity, mature regulatory systems, and high-value biologics and advanced therapy pipelines, while NATO-aligned supply chain planning increasingly influences procurement resilience for critical medicines, emergency preparedness, and strategic health security.

Key Country Insights for Pharmaceutical CDMOs

The United States is the leading innovation-driven CDMO demand center, supported by FDA-regulated development, biologics pipelines, venture-backed biotechnology, orphan drug activity, and reshoring incentives for critical medicines. Canada contributes specialized research, clinical manufacturing, and a supportive biotechnology ecosystem, while Mexico benefits from proximity to the U.S. market, established manufacturing capabilities, and growing interest in nearshore pharmaceutical supply. Brazil is Latin America’s principal pharmaceutical market, with domestic demand, public health procurement, biosimilar interest, and regulatory modernization supporting outsourced manufacturing opportunities.

In Europe, the United Kingdom remains strong in biotech innovation, clinical development, and advanced therapies. Germany is a major hub for pharmaceutical engineering, biologics, and high-quality manufacturing, while France supports vaccines, biologics, and policy-backed industrial renewal. Italy and Spain are established centers for contract manufacturing, sterile products, and pharmaceutical exports, and Russia remains focused on domestic production under import substitution policy. In Asia-Pacific, China offers large-scale development and biologics capacity, India anchors APIs, generics, vaccines, and cost-efficient CDMO services, Japan demands high-quality specialized manufacturing and strong compliance discipline, Australia supports clinical-stage development and early-phase trial activity, and South Korea has built globally competitive biologics manufacturing capacity supported by advanced infrastructure and policy focus.

Actionable Recommendations for CDMO Leaders

Industry vendors should prioritize resilient capacity planning by balancing cost efficiency with dual sourcing, geographic diversification, and validated business continuity. CDMOs should invest in high-demand capabilities including sterile fill-finish, biologics, antibody-drug conjugates, high-potency manufacturing, analytical services, and cold-chain-ready packaging. Sponsors should evaluate partners using inspection performance, technology transfer maturity, batch success rates, data integrity, regulatory documentation quality, and scalability rather than price alone.

Vendors should also build AI and automation roadmaps tied to measurable quality and productivity outcomes. Recommended priorities include digital batch records, predictive maintenance, advanced process control, deviation analytics, secure data platforms, and validated model governance. To sustain differentiation, CDMOs should strengthen talent pipelines, align with ICH quality standards, improve environmental performance, and create transparent governance models for long-term sponsor partnerships.

Research Methodology and Evidence Base

This executive summary is based on a structured synthesis of public regulatory guidance, industry disclosures, government manufacturing policies, pharmaceutical trade patterns, inspection priorities, and recognized quality frameworks. Core reference points include FDA and EMA regulatory expectations, ICH guidelines, WHO manufacturing and access priorities, national life sciences strategies, publicly available capacity announcements, and observed sponsor outsourcing behavior across small molecules, biologics, sterile products, vaccines, and advanced therapies.

The methodology applies triangulation across demand-side indicators, supply-side capacity signals, regional policy developments, regulatory requirements, and technology adoption trends. Insights are evaluated through market relevance, regulatory credibility, manufacturing feasibility, and strategic importance to pharmaceutical sponsors and CDMOs. The analysis avoids unsupported projections and focuses on verifiable, decision-useful patterns shaping pharmaceutical contract development and manufacturing competitiveness.

Conclusion: Strategic Outlook for Pharmaceutical CDMOs

Pharmaceutical contract development and manufacturing is entering a more strategic era defined by scientific complexity, capacity constraints, quality expectations, and supply chain resilience. The market is expanding from conventional outsourcing into integrated partnerships that support development acceleration, regulatory readiness, and commercial reliability across global and regional networks.

CDMOs that combine specialized infrastructure, regulatory excellence, digital maturity, and geographic flexibility will be best positioned to capture growth. Sponsors that select partners through a risk-adjusted lens can improve speed, compliance, and supply continuity while navigating a more complex pharmaceutical manufacturing environment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Pharmaceutical Contract Development & Manufacturing Market, by Service Type
7.1. Introduction
7.2. Contract Development Services
7.2.1. Analytical Development
7.2.2. Clinical Trial Material Manufacturing
7.2.3. Drug Formulation Development
7.2.4. Process Development
7.3. Contract Manufacturing Services
7.3.1. Active Pharmaceutical Ingredient (API) Manufacturing
7.3.2. Finished Dosage Form (FDF) Manufacturing
7.3.3. Packaging Services
8. Pharmaceutical Contract Development & Manufacturing Market, by Molecule Type
8.1. Introduction
8.2. Small Molecules
8.3. Biologics
8.4. Peptides
8.5. Oligonucleotides
8.6. Cell Therapies
8.7. Gene Therapies
9. Pharmaceutical Contract Development & Manufacturing Market, by Development Stage
9.1. Introduction
9.2. Clinical
9.2.1. Phase I
9.2.2. Phase II
9.2.3. Phase III
9.3. Commercial
9.4. Preclinical
10. Pharmaceutical Contract Development & Manufacturing Market, by Temperature Requirement
10.1. Introduction
10.2. Ambient
10.3. Refrigerated
10.4. Frozen
10.5. Cryogenic
11. Pharmaceutical Contract Development & Manufacturing Market, by Production Mode
11.1. Introduction
11.2. Batch Manufacturing
11.3. Continuous Manufacturing
12. Pharmaceutical Contract Development & Manufacturing Market, by End Use
12.1. Introduction
12.2. Cardiovascular
12.3. Central Nervous System
12.4. Infectious Diseases
12.5. Oncology
13. Pharmaceutical Contract Development & Manufacturing Market, by Region
13.1. Asia-Pacific
13.2. North America
13.3. Latin America
13.4. Europe
13.5. Middle East
13.6. Africa
14. Pharmaceutical Contract Development & Manufacturing Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Pharmaceutical Contract Development & Manufacturing Market, by Country
15.1. United States
15.2. China
15.3. India
15.4. Germany
15.5. United Kingdom
15.6. Canada
15.7. Japan
15.8. Australia
15.9. France
15.10. Italy
15.11. Brazil
15.12. Mexico
15.13. Russia
15.14. Spain
15.15. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AbbVie, Inc.
17.2. Aenova Holding GmbH
17.3. Almac Group
17.4. Amgen Inc.
17.5. Baxter International Inc.
17.6. Biozoc Inc.
17.7. Boehringer Ingelheim International GmbH
17.8. Cambrex Corporation
17.9. Catalent, Inc.
17.10. Curia Global, Inc.
17.11. Danaher Corporation
17.12. Dr. Reddy’s Laboratories Ltd.
17.13. Elkos Group
17.14. Evonik Industries AG
17.15. Famar Group
17.16. Fareva Group
17.17. Jubilant Pharma Limited
17.18. Kryptochem Medicament Pvt. Ltd.
17.19. Lonza Group
17.20. Midas Pharma GmbH
17.21. Nipro Group
17.22. Novartis AG
17.23. Pfizer Inc.
17.24. Pidolma Healthcare
17.25. PYRAMID Laboratories, Inc.
17.26. Recipharm AB
17.27. Siegfried Holding AG
17.28. Thermo Fisher Scientific Inc.
17.29. Vetter Pharma-Fertigung GmbH & Co. KG
17.30. WuXi AppTec Co., Ltd
List of Figures
FIGURE 1. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2025 VS 2032 (%)
FIGURE 13. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2025 VS 2032 (%)
FIGURE 17. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CONTRACT DEVELOPMENT SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CONTRACT DEVELOPMENT SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CONTRACT DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL ANALYTICAL DEVELOPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL ANALYTICAL DEVELOPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL ANALYTICAL DEVELOPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL CLINICAL TRIAL MATERIAL MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL CLINICAL TRIAL MATERIAL MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL CLINICAL TRIAL MATERIAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL DRUG FORMULATION DEVELOPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL DRUG FORMULATION DEVELOPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL DRUG FORMULATION DEVELOPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL CONTRACT MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL CONTRACT MANUFACTURING SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL CONTRACT MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT (API) MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT (API) MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT (API) MANUFACTURING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL FINISHED DOSAGE FORM (FDF) MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL FINISHED DOSAGE FORM (FDF) MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL FINISHED DOSAGE FORM (FDF) MANUFACTURING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL PACKAGING SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL PACKAGING SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL PACKAGING SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL PEPTIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL PEPTIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL PEPTIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL OLIGONUCLEOTIDES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL OLIGONUCLEOTIDES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL OLIGONUCLEOTIDES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL CELL THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL CELL THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL CELL THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL GENE THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL GENE THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL GENE THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL CLINICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL CLINICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL CLINICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL PHASE I MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL PHASE I MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL PHASE I MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL PHASE II MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL PHASE II MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL PHASE II MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL PHASE III MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL PHASE III MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL PHASE III MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL COMMERCIAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL COMMERCIAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL COMMERCIAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL PRECLINICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL PRECLINICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL PRECLINICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL AMBIENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL AMBIENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL AMBIENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL REFRIGERATED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL REFRIGERATED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL REFRIGERATED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL FROZEN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL FROZEN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL FROZEN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL CRYOGENIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL CRYOGENIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL CRYOGENIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL BATCH MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL BATCH MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL BATCH MANUFACTURING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL CONTINUOUS MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL CONTINUOUS MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 105. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2017-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 107. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2017-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2017-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2017-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 113. NORTH AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. NORTH AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 115. NORTH AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2017-2032 (USD MILLION)
TABLE 116. NORTH AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 117. NORTH AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 118. NORTH AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 119. NORTH AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2017-2032 (USD MILLION)
TABLE 120. NORTH AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2017-2032 (USD MILLION)
TABLE 121. NORTH AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2017-2032 (USD MILLION)
TABLE 122. NORTH AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 123. LATIN AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 124. LATIN AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 125. LATIN AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2017-2032 (USD MILLION)
TABLE 126. LATIN AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 127. LATIN AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 128. LATIN AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 129. LATIN AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2017-2032 (USD MILLION)
TABLE 130. LATIN AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2017-2032 (USD MILLION)
TABLE 131. LATIN AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2017-2032 (USD MILLION)
TABLE 132. LATIN AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 133. EUROPE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 134. EUROPE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 135. EUROPE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2017-2032 (USD MILLION)
TABLE 136. EUROPE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 137. EUROPE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 138. EUROPE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 139. EUROPE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2017-2032 (USD MILLION)
TABLE 140. EUROPE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2017-2032 (USD MILLION)
TABLE 141. EUROPE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2017-2032 (USD MILLION)
TABLE 142. EUROPE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 143. MIDDLE EAST PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 144. MIDDLE EAST PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 145. MIDDLE EAST PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2017-2032 (USD MILLION)
TABLE 146. MIDDLE EAST PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 147. MIDDLE EAST PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 148. MIDDLE EAST PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 149. MIDDLE EAST PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2017-2032 (USD MILLION)
TABLE 150. MIDDLE EAST PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2017-2032 (USD MILLION)
TABLE 151. MIDDLE EAST PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2017-2032 (USD MILLION)
TABLE 152. MIDDLE EAST PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 153. AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 154. AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 155. AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2017-2032 (USD MILLION)
TABLE 156. AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 157. AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 158. AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 159. AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2017-2032 (USD MILLION)
TABLE 160. AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2017-2032 (USD MILLION)
TABLE 161. AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2017-2032 (USD MILLION)
TABLE 162. AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 163. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 164. ASEAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 165. ASEAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 166. ASEAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2017-2032 (USD MILLION)
TABLE 167. ASEAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 168. ASEAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 169. ASEAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 170. ASEAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2017-2032 (USD MILLION)
TABLE 171. ASEAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2017-2032 (USD MILLION)
TABLE 172. ASEAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2017-2032 (USD MILLION)
TABLE 173. ASEAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 174. GCC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 175. GCC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 176. GCC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2017-2032 (USD MILLION)
TABLE 177. GCC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 178. GCC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 179. GCC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 180. GCC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2017-2032 (USD MILLION)
TABLE 181. GCC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2017-2032 (USD MILLION)
TABLE 182. GCC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2017-2032 (USD MILLION)
TABLE 183. GCC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2017-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2017-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2017-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2017-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 194. BRICS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 195. BRICS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 196. BRICS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2017-2032 (USD MILLION)
TABLE 197. BRICS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 198. BRICS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 199. BRICS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 200. BRICS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2017-2032 (USD MILLION)
TABLE 201. BRICS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2017-2032 (USD MILLION)
TABLE 202. BRICS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2017-2032 (USD MILLION)
TABLE 203. BRICS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 204. G7 PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 205. G7 PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 206. G7 PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2017-2032 (USD MILLION)
TABLE 207. G7 PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 208. G7 PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 209. G7 PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 210. G7 PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2017-2032 (USD MILLION)
TABLE 211. G7 PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2017-2032 (USD MILLION)
TABLE 212. G7 PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2017-2032 (USD MILLION)
TABLE 213. G7 PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 214. NATO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 215. NATO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 216. NATO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2017-2032 (USD MILLION)
TABLE 217. NATO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 218. NATO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 219. NATO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 220. NATO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2017-2032 (USD MILLION)
TABLE 221. NATO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2017-2032 (USD MILLION)
TABLE 222. NATO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2017-2032 (USD MILLION)
TABLE 223. NATO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 224. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 225. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 226. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 227. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2017-2032 (USD MILLION)
TABLE 228. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 229. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 230. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 231. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2017-2032 (USD MILLION)
TABLE 232. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2017-2032 (USD MILLION)
TABLE 233. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2017-2032 (USD MILLION)
TABLE 234. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 235. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 236. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 237. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2017-2032 (USD MILLION)
TABLE 238. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 239. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 240. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 241. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2017-2032 (USD MILLION)
TABLE 242. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2017-2032 (USD MILLION)
TABLE 243. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2017-2032 (USD MILLION)
TABLE 244. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 245. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 246. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 247. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2017-2032 (USD MILLION)
TABLE 248. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 249. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 250. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 251. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2017-2032 (USD MILLION)
TABLE 252. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2017-2032 (USD MILLION)
TABLE 253. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2017-2032 (USD MILLION)
TABLE 254. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 255. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 256. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 257. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2017-2032 (USD MILLION)
TABLE 258. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 259. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 260. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 261. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2017-2032 (USD MILLION)
TABLE 262. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2017-2032 (USD MILLION)
TABLE 263. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2017-2032 (USD MILLION)
TABLE 264. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 265. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 266. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 267. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2017-2032 (USD MILLION)
TABLE 268. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 269. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 270. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 271. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2017-2032 (USD MILLION)
TABLE 272. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2017-2032 (USD MILLION)
TABLE 273. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2017-2032 (USD MILLION)
TABLE 274. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 275. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 276. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 277. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2017-2032 (USD MILLION)
TABLE 278. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 279. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 280. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2017-2032 (USD MILLION)
TABLE 281. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2017-2032 (USD MILLION)
TABLE 282. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2017-2032 (USD MILLION)
TABLE 283. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2017-2032 (USD MILLION)
TABLE 284. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 285. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 286. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 287. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVI

Companies Mentioned

  • AbbVie, Inc.
  • Aenova Holding GmbH
  • Almac Group
  • Amgen Inc.
  • Baxter International Inc.
  • Biozoc Inc.
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • Curia Global, Inc.
  • Danaher Corporation
  • Dr. Reddy’s Laboratories Ltd.
  • Elkos Group
  • Evonik Industries AG
  • Famar Group
  • Fareva Group
  • Jubilant Pharma Limited
  • Kryptochem Medicament Pvt. Ltd.
  • Lonza Group
  • Midas Pharma GmbH
  • Nipro Group
  • Novartis AG
  • Pfizer Inc.
  • Pidolma Healthcare
  • PYRAMID Laboratories, Inc.
  • Recipharm AB
  • Siegfried Holding AG
  • Thermo Fisher Scientific Inc.
  • Vetter Pharma-Fertigung GmbH & Co. KG
  • WuXi AppTec Co., Ltd

Table Information

Report AttributeDetails
No. of Pages182
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 160.2 Billion
Forecasted Market Value ( USD ) by 2032 $ 265.79 Billion
Compound Annual Growth Rate8.7%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

Pharmaceutical Contract Development and Manufacturing Organization Market Size, Share & Trends Analysis Report by Type, Product, Service, Workflow, Therapeutic Area, End Use, Region, and Segment Forecasts, 2025-2033 - Product Image

Pharmaceutical Contract Development and Manufacturing Organization Market Size, Share & Trends Analysis Report by Type, Product, Service, Workflow, Therapeutic Area, End Use, Region, and Segment Forecasts, 2025-2033

  • Report
  • 120 Pages
  • Global
From
Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook 2026-2034: Market Share, and Growth Analysis by Service Type, Molecule Type, Dosage Form, Therapeutic Area - Product Image

Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook 2026-2034: Market Share, and Growth Analysis by Service Type, Molecule Type, Dosage Form, Therapeutic Area

  • Report
  • 160 Pages
  • Global
From
Pharmaceutical Contract Development and Manufacturing Organization (CDMO) for Formulations Market Report 2026 - Product Image

Pharmaceutical Contract Development and Manufacturing Organization (CDMO) for Formulations Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Pharmaceutical Contract Development and Manufacturing Organization (CDMO) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Pharmaceutical Contract Development and Manufacturing Organization (CDMO) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 317 Pages
  • Global
From
Pharmaceutical Contract Development and Manufacturing Organization (CMO) Market Report 2026 - Product Image

Pharmaceutical Contract Development and Manufacturing Organization (CMO) Market Report 2026

  • Report
  • 250 Pages
  • Global
From

About the Pharmaceutical Contract Management Market

The Pharmaceutical Contract Management market is an important part of the drug discovery process. It involves the management of contracts between pharmaceutical companies and research organizations, such as universities and biotechnology companies. These contracts are used to facilitate the development of new drugs and treatments. The contract management process includes the negotiation of terms, the management of payments, and the tracking of progress. It also involves the management of intellectual property rights, such as patents and copyrights. The Pharmaceutical Contract Management market is highly competitive, with many companies offering services to pharmaceutical companies. These companies provide a range of services, including contract negotiation, contract management, and intellectual property management. Some of the leading companies in the market include Accenture, Deloitte, Parexel, and Syneos Health. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.